REGN


RBC Capital Maintains Outperform on Regeneron Pharmaceuticals Inc Following FDA Approval Recommendation for Praluent

RBC Capital analyst Adnan Butt came out with a research report on Regeneron Pharmaceuticals Inc (NASDAQ:REGN) following an FDA panel recommendation for the approval of Regeneron …

Company Update (NASDAQ:REGN): Trading in Regeneron Pharmaceuticals Inc Common Stock Halted

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that NASDAQ has halted trading of the company’s common stock.  The Endocrinologic and Metabolic Drugs Advisory Committee of the …

BMO Capital Remains On The Sidelines With Regeneron Pharmaceuticals Inc (REGN) Following FDA Briefing Documents Release

BMO Capital analyst Jim Birchenough came out today with a research report on Regeneron Pharmaceutals Inc (NASDAQ:REGN), reiterating a Market Perform rating on the stock with a …

Biotech Beat: Oncothyreon Inc (USA), Innate Pharma SA, Regeneron Pharmaceuticals Inc and Merck & Co., Inc. News

Biotech has been in a funk for over a week now, though Friday finished strong. iShares’ NASDAQ Biotechnology ETF (IBB) has been stuck …

Stock Update (NASDAQ:REGN): Regeneron Pharmaceuticals Inc and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi announced that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary …

Biotech Stock Roundup: Biogen Soars on Alzheimer’s Data, Gilead HCV Drugs Label Update

It’s been an eventful week on the pipeline front with companies like Biogen Inc (NASDAQ:BIIB), Prothena Corporation PLC (NASDAQ:PRTA) and Vertex Pharmaceuticals Incorporated …

A Roundup of Our Top Stories in Healthcare From the Week

One of the more anticipated events of early 2015 played out on Friday – detailed results from an early study of Biogen Idec Inc's (NASDAQ:BIIB) experimental …

Chardan Capital Initiates Buy on Regeneron Pharmaceuticals Inc; Sees 15% Upside For The Stock

In a research report issued Friday, Chardan Capital analyst Gbola Amusa initiated coverage on shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) with a Buy rating and a price target …

Retrophin’s Busy Week: A Financing, a Drug Approval and a Valuable FDA Voucher

Just a day after Retrophin Inc. (NASDAQ:RTRX) announced a $100 million financing the U.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts